Conjugated Linoleic Acid and Dietary Beef
– An Update
Denver Office Chicago Office Washington D.C. Office
P.O. Box 3469 444 North Michigan Avenue 1301 Pennsylvania Avenue, N.W.
Englewood, CO 80155 Chicago, Illinois 60611 Suite #300
(303) 694-0305 (312) 467-5520 Washington, DC 20004
(202) 347-0228 11-424 1995.0
Conjugated linoleic acid (CLA), a natural derivative of the fatty acid linoleic acid, has received increasing attention in recent years. Starting with anticarcinogenic effects, the potential benefits of this unique fatty acid have extended to antiatherogenic properties, anti-diabetic properties, enhanced immune response and positive effects on energy partitioning and growth.
These effects have been documented in numerous reviews (1-4) as well as in extensive scientific literature that has grown exponentially since the late 1980’s (5). As a naturally occurring compound in foods from
ruminant animal sources, CLA’s anticarcinogenic properties are unique. Of the vast number of naturally occurring substances, demonstrated to have anti-carcinogenic activity, all but a very few are of plant origin (1).
Chemistry/Structure
CLA is a collective term used to describe a mixture of positional and geometric isomers/forms of linoleic acid. Linoleic acid is an 18-carbon unsaturated fatty acid with two double bonds in positions 9 and 12, both
in the “cis” (on same side) configuration. Thus, the “chemical name” of linoleic acid is cis-9, cis-12-octadecadienoic acid. In contrast, the two double bonds in CLA are primarily in positions 9 and 11, and 10 and 12 along the carbon chain with the designation of a conjugated
diene. In addition to these “positional” changes of the double bonds, there can also be geometric changes (cis(c) or trans(t) [on opposite sides] configuration). Thus, at least eight different CLA isomers of linoleic
acid have been identified. Of these isomers, the c9, t11 form is believed to be the most common natural form of CLA, with biological activity. However, in recent years, biological activity has been proposed for
other forms, especially the t10, c12 isomer. Although not widely accepted, the name “rumenic acid” has been proposed as a “common name” for the major CLA isomer found in natural products (6). For a comparison of these CLA isomer “forms” with linoleic acid, see Figure
1. Additional potentially active isomers are also being identified and studied (2,7). Figure 1. Chemical Structures of Linoleic Acid and Two Isomers of Conjugated Linoleic Acid (CLA). * Linoleic acid (c-9, c-12) Conjugated linoleic acid Conjugated linoleic acid octadecadienoic acid c-9, t-11 isomer t-10, c-12 isomer * Adapted from: Steinhart, C. Conjugated Linoleic Acid The Good News about Animal Fat. J.Chem.Educ. 73:A302; 1996. 2 Table 1. Representative/Relative Concentrations of CLA in Uncooked Foods [adapted from Chin et al. (12)].
Total CLA c9, tll-isomer
Food (mg/g fat) (%)
Meat
Fresh ground beef 4.3 85
Beef round 2.9 79
Beef frank 3.3 83
Beef smoked sausage 3.8 84
Veal 2.7 84
Lamb 5.6 92
Pork 0.6 82
Poultry
Chicken 0.9 84
Fresh ground turkey 2.5 76
Seafood
Salmon 0.3 n.d.*
Lake trout 0.5 n.d.
Shrimp 0.6 n.d.
Dairy Products
Homogenized milk 5.5 92
Butter 4.7 88
Sour cream 4.6 90
Plain yogurt 4.8 84
Ice cream 3.6 86
Sharp cheddar cheese 3.6 93
Mozzarella cheese 4.9 95
Colby cheese 6.1 92
Cottage cheese 4.5 83
Reduced fat swiss 6.7 90
Am. Processed cheese 5.0 93
Cheez whizTM 5.0 92
Vegetable Oils
Safflower 0.7 44
Sunflower 0.4 38
Canola 0.5 44
Corn 0.2 39
* n.d. => not detectable
History/Identification/Sources
CLA is a naturally occurring fatty acid found in food products from ruminants (cattle and sheep). Although identified much earlier, increased interest in CLA occurred when it was isolated and identified by Pariza
and coworkers as an anticarcinogenic substance from grilled ground beef (8-10). It was also found to be present in a variety of dairy products (11).
The total CLA content in foods may vary widely. Representative and relative concentrations of CLA in a variety of foods are summarized in Table 1. CLA concentrations are highest in foods from ruminants (including beef, lamb and dairy products). Seafoods, pork, most poultry products and vegetable oils are not notable sources of CLA (12). CLA has been found in triglycerides, lipoproteins and cell membrane phospholipids in various tissues of rodents, rabbits and humans (2). As a normal isomerization product of linoleic acid metabolism by rumen bacteria, CLA is synthesized from free linoleic acid through biohydrogenation pathways and enzymatic isomerization. Early studies suggested that CLA content could be increased in foods that are heat processed (dairy pasteurization, pan frying of meats, etc.) (11). However, later studies (13) suggest that CLA is not increased by cooking, but rather with water loss, CLA remains constant on a per gram of fat basis. Additionally, CLA is stable and not destroyed by cooking or storage. Foods from ruminant sources (beef and dairy) generally have CLA levels in the range of 3-7 mg/g fat; although, recent studies have shown it may be possible to increase these “naturally” occurring levels (4,14-16).
Multisite Anticarcinogen – Cell and Animal Studies Following the initial identification of CLA as a modulator of mutagenensis and carcinogenesis, research interest accelerated. Additional studies confirmed this anticarcinogen effect in a variety of tissues, especially skin and forestomach. Continuing work with a wide variety of cell cultures and cancer cell lines (including malignant melanoma, colorectal cancer, breast/mammary cancer, lung adenocarcinoma, prostate cancer,
leukemia, ovarian and liver cancers) have demonstrated inhibition by CLA (3,17-20). In contrast, linoleic acid did not inhibit the growth of any cell line and in some cases stimulated tumor growth and metastasis (18,21). Perhaps the most significant
early anticarcinogenic effects of CLA were described by Ip and co-workers (22,23) where CLA prevented mammary cancer in rodents given CLA in the diet, prior to administration of a carcinogen. This contrasted with earlier studies that used acute dosing by direct contact, gavage, or via cell culture additions. These dietary studies found a dose-dependent protection at levels of 1% CLA and below, but no further beneficial effect was evident at levels above 1%. In studies with dietary CLA at 0.05, 0.1, 0.25 and 0.5%, as little as 0.1% CLA was sufficient to cause a significant reduction in mammary tumors. This confirmed CLA as a powerful anticarcinogen, which could be administered safely via the diet to achieve cancer protection, in an animal model. To put in perspective, the effect of CLA (an animal fat) in cancer prevention is specific and is more powerful than for any other fatty acid in modulating tumor development (1). For instance, unlike linoleic acid (a 3 close relative of CLA) which sometimes stimulates carcinogenesis (21), CLA is inhibitory. Also, the n-3 fatty acids of fish oil, which generally are responsible for tumor suppression, require in excess of 10% in the diet to elicit the same tumor suppression responses. In contrast, CLA at levels as low as 0.1% in the diet produce a significant reduction in mammary tumor yield in animal studies. Further work by Ip and co-workers has shown that the timing of CLA feeding can be critical. For instance, when CLA is given during the time the mammary tissue is actively developing, you see a lasting protective effect. If CLA is given after carcinogen administration, a continual supply of CLA is needed for a preventive effect. CLA appears to have a major impact on the mammary gland, making the tissue less susceptible to tumor formation (4,23,24). Work continues to determine the exact mechanism by which CLA may effect carcinogen metabolism, activation or detoxification (2,3,25). Studies with mice given CLA, prior to administration of the heterocyclic amine IQ, have shown varying reductions in IQ-DNA adducts in the liver, lung, large and small intestine, kidneys and colon (26,27). CLA at levels equivalent to 0.5% of the diet, exerted inhibitory effects on the process of colon carcinogenesis (27). Other Beneficial Effects of CLA Antiatherogenic and
Hypocholesterolemic
Based on the possibility that CLA would exhibit antioxidant activity, both in vivo and in vitro (22,28), studies were initiated to examine the effect of CLA on experimental atherogenesis in rabbits (29). When CLA, was
added at 0.5% to an atherogenic diet, for 12 weeks, the aortas of the CLA fed rabbits exhibited less atherosclerosis. Also, LDL (low-density lipoprotein) cholesterol and triglycerides (TG) were lower in the CLA fed group (29). This observation was later supported by studies in hamsters
where CLA feeding resulted in lower plasma total and LDL cholesterol and TG levels (30). The CLA fed animals also had less aortic streak formation.
Fat Partitioning and Metabolism
One of the most interesting effects of CLA appears to be its influence on body fat levels and the proportion of lean to fat, especially in young growing animals. CLA induces a relative decrease in body fat levels
and an increase in lean muscle. This observation has been noted in several studies with mice, rats, chicks and pigs (4,31-33). In a study with growing pigs, the results were quite dramatic. Backfat thickness was reduced up to 27% in CLA fed pigs and there was a 6.8% increase in percent lean (33). Such results have generated considerable interest as to whether humans will experience similar fat reductions and increases in proportion of muscle mass if CLA is consumed in the diet. Studies in humans are currently underway (4). Effects on Immune Response and Bone Formation The effects of CLA on fat partitioning may be at least partially the result of modulation of the immune system. Ordinarily, stimulation of the immune system produces cytokines (proteins released by a cell, upon contact with an antigen, acts as a mediator) which can
cause breakdown of muscle cells. CLA can modulate (decrease) the production of cytokines and thus prevent muscle degradation. Experiments in chicks, rats, and mice show that CLA increases feed efficiency and counteracts immune-induced cachexia or malnutrition (4,31,34). Through this effect on cytokines, CLA may also have positive effects on bone health (4,35,36). Diets rich in fats containing CLA, compared to soybean oil, caused a greater rate of bone formation (4).
Anti-diabetic Effects
CLA has been found to help normalize or reduce blood glucose levels and possibly prevent diabetes (37). Using a laboratory animal model for diabetes, CLA was found to prevent the onset of diabetes. CLA appears to
work as well as a new class of diabetes-fighting drugs (thiazolidinediones) and may provide the added advantage of weight reduction, as drug treatments often result in weight gain. These initial findings with diabetic
rats are very encouraging and are the basis for continuing studies in human diabetics.
Other Human Studies – Epidemiology/ BREAST MILK IN WOMEN
Epidemiological studies support the hypothesis that there is some factor in whole milk that exerts a protective effect against breast cancer and coronary heart disease (4,38,39). Lower incidences of these diseases were
related to greater consumption of whole milk but not to intakes of low fat milk. The presence of CLA in milkfat may be a protective factor. In a recent report the incidence of breast cancer was significantly lower in women with higher breast tissue levels of CLA (40). It is clear that the CLA content of blood serum and breast milk can be modified by diet (41-43). In earlier studies in Australia, it had been found that breast milk from women of the Hare Krishna religious sect contained twice as much CLA as milk from Australian mothers on conventional diets (11.2 vs. 5.8 mg/g) (44). This 4 was attributed to the large amount of butter and ghee (a clarified butter) consumed by the Hare Krishna. Park and coworkers (43) have also confirmed that CLA levels in human milk can be enhanced by increasing the CLA content of the maternal diet. Effective Intake/Dose Levels For any compound that produces the dramatic effects noted for CLA, an immediate question concerns the minimally effective dose level. Does it vary for different health and disease conditions, tissue sites and response levels? Is a “chronic” dose level required, or can an “acute” dose be effective and if so, when should it be consumed? Are food sources adequate or are supplemental sources required? If only some of the isomers of CLA are biologically effective, which ones are they? If so, dose levels of CLA should be “corrected” for the active isomer. Whether from food sources or supplements, any comparisons of effects should be sure to equate levels of the active isomer. These are just some of the many questions about CLA which require further research. Usual Dietary Intakes Current measures of usual or actual dietary intakes of CLA are very limited, most being only estimates. A listing of published reports based on estimates and data analysis is presented in Table 2. (10,45-49).
A variety of factors can influence estimates of CLA intake. Food composition and frequency of intake of particular foods affect dietary intake of any food component. For CLA, there may be the added variable of level of the biologically active form/isomer of CLA consumed. Also, men usually consume more meat than women do; dairy foods generally provide a higher percentage of dietary CLA than beef; and individuals may be beef or dairy users or non-users. In addition, intake estimates may be based on assumptions of dietary proportions, such as in the German studies of meat/meat products (40/60) and pork/beef (80/20) (47). In another study (48), available data on CLA content of foods has been applied to consumption data from the USDA CSFII 94-96 (Continuing Survey of Food Intake of Individuals). Based on intake data from this large dataset it is estimated that approximately 36% of total CLA intake is from beef and approximately 52% from dairy products. Dietary Beef as a Source Can a reasonable diet, containing beef, provide beneficial levels of CLA, considering that the minimal effective dose response is still unknown? At present, the answer would be “probably”, but more studies are needed to determine minimally effective levels of CLA. Animal studies have shown benefits at dietary levels as low as 0.1-0.5%. Also, the potential for CLA enhanced, (but still “natural”), dietary sources of beef and dairy products is just now being explored (4). It has been shown that a number of dietary components for cattle can increase CLA levels in milk and beef. These include:
plants consumed in pasture, forage in feeds, and unsaturated plant oils (with sunflower oil resulting in the most CLA). CLA concentrations in milk have been increased up to four fold by various dietary manipulations (4,14). Increases in the CLA content of beef tissue is currently being explored, with preliminary indications that elevations in CLA content are possible via feeding practices (16). Table 2. Estimates of CLA Intake in Humans. Reference Population Studied Males Females All mg/day 10 Not specified — — “several hundred mg/day” 45 Australian (not specified) — 500-1500 46 German men 310 — —
47 German men & women 430 350 — (from meat) 110 80 —
(from dairy) 286 240 — 48 CSFII 94-96 (beef users) 265 172 221
Men & women (non-beef users) 123 88 102 49 Adults 18-60 yr. 3-day record 137 79 — (mean 31 yr.) 3-day duplicate 148 132 —
FFQ 197 93 — 5
Summary
CLA is a very unique fatty acid from ruminant animal sources that exhibits powerful anticarcinogenic effects at relatively low dietary levels. In addition, CLA has been shown to be anti-atherogenic, anti-diabetic and to provide beneficial effects on growth, health and body-fat levels and proportion of lean to fat. Much remains to be learned about the exact mechanisms by which CLA exerts its effects (25). In addition, the exciting findings from animal studies need to be replicated, as appropriate, in humans. Dietary beef represents one of the primary “natural” sources of this intriguing compound which some have called a “previously unrecognized nutrient” (50).
References
1.) Ip, C.; Scimeca, J.A.; Thompson, H.J. Conjugated linoleic acid. A
powerful anticarcinogen from animal fat sources. Cancer. 74:1050-
1054; 1994.
2.) Belury, M.A. Conjugated dienoic linoleate: a polyunsaturated fatty
acid with unique chemoprotective properties. Nutr. Rev. 53:83-
89:1995.
3.) Parodi, P.W. Milk fat conjugated linoleic acid: can it help prevent
breast cancer? Proceed. Nutr. Soc. New Zealand. 22:137-149; 1997.
4.) Doyle, E. Scientific forum explores CLA knowledge. INFORM
9(1):69-73; 1998.
5.) Food Research Institute, University of Wisconsin, Madison.
References on conjugated linoleic acid (CLA). FRI home page, (http://
www.wisc.edu/fri/clarefs.htm) 1998.
6.) Kramer, J.K.G.; Parodi, P.W.; Jensen, R.G.; Mossoba, M.M.;
Yurawecz, M.P.; Adlof, R.O. Rumenic acid: a proposed common name
for the major conjugated linoleic acid isomer found in natural
products. Lipids 33:835; 1998.
7.) Yurawecz, M.P.; Roach, J.A.G.; Sehat, N.; Mossoba, M.M.; Kramer,
J.K.G.; Fritsche, J.; Steinhart, H.; Ku, Y. A new conjugated linoleic acid
isomer, 7 trans, 9 cis-octadecadienoic acid, in cow milk, cheese, beef
and human milk and adipose tissue. Lipids 33:803-809; 1998.
8.) Pariza, M.W.; Loretz, L.J.; Storkson, J.M.; Holland, N.C. Mutagens
and modulator of mutagenesis in fried ground beef. Cancer Res.
43:2444s-2446s;1983.
9.) Pariza, M.W.; Hargraves, W.A. A beef-derived mutagenesis
modulator inhibits initiation of mouse epidermal tumors by 7,12-
dimethylbenz[a]anthracene. Carcinogenesis 6:591-593; 1985.
10.) Ha, Y.L.; Grimm, N.K.; Pariza, M.W. Anticarcinogens from fried
ground beef: heat-altered derivatives of linoleic acid. Carcinogenesis
8:1881-1887; 1987.
11.) Ha, Y.L.; Grimm, N.K.; Pariza, M.W. Newly recognized
anticarcinogenic fatty acids: identification and quantification in
natural and processed cheeses. J. Agr. Food Chem. 37:75-81; 1989.
12.) Chin, S.F.; Liu, W.; Storkson, J.M.; Ha, Y.L.; Pariza, M.W. Dietary
sources of conjugated dienoic isomers of linoleic acid, a newly
recognized class of anticarcinogens. J. Food Comp. Anal. 5:185-197;
1992.
13.) Shantha, N.C.; Crum, A.D.; Decker, E.A. Evaluation of conjugated
linoleic acid concentrations in cooked beef. J.Agric. Food Chem.
42(8):1757-1760; 1994.
14.) Kelly, M.L.; Berry, J.R.; Dwyer, D.A.; Griinari, J.M.; Chouinard,
P.Y.; Vanamburgh, M.E.; Bauman, D.E. Dietary fatty acid sources affect
conjugated linoleic acid concentrations in milk from lactating dairy
cows. J. Nutr. 128:881-885; 1998.
15.) Dhiman, T.R.; Satter, L.D.; Pariza, M.W.; Gali, M.P.; Albright, K.
Conjugated linoleic acid (CLA) content of milk from cows offered diets
rich in linoleic and linolenic acid. J. Dairy Sci. 80(suppl 1):184 (abstr.);
1998.
16.) Dhiman, T.R. Dietary influence on conjugated linoleic acid
content of milk and meat. AOCS 89th Annual Mtg. Presentation,
(abstr.); 1998.
17.) Shultz, T.D.; Chew, B.P.; Seaman, W.R.; Luedecke, L.O. Inhibitory
effect of conjugated dienoic derivatives of linoleic acid and bcarotene
on the in vitro growth of human cancer cells. Cancer Letters
63:125-133; 1992.
18.) Schonberg, S.; Krokan, H.E. The inhibitory effect of conjugated
dienoic derivatives (CLA) of linoleic acid on the growth of human
tumor cell lines is in part due to increased lipid peroxidation.
Anticancer Research 15:1241-1246; 1995.
19.) Visonneau, S.; Cesano, A.; Tepper, S.A.; Scimeca, J.; Kritchevsky,
D. Effect of different concentrations of conjugated linoleic acid (CLA)
on tumor cell growth in vitro. FASEB J. 9:A869; 1996.
20.) Yoon, C.S.; Ha, T.Y.; Rho, J.H.; Sung, K.S.; Cho, I.J. Inhibitory
effect of conjugated linoleic acid on in vitro growth of human
hepatoma. FASEB J. 11:A578; 1997.
21.) Ip, C.; Carter, C.A.; Ip, M.M. Requirement of essential fatty acid
for mammary tumorigenesis in the rat. Cancer Res. 45:1997-2001;
1985.
22.) Ip, C.; Chin, S.F.; Scimeca, J.A.; Pariza, M.W. Mammary cancer
prevention by conjugated dienoic derivative of linoleic acid. Cancer
Res. 51:6118-6124; 1991.
23.) Ip, C.; Singh, M.; Thompson, H.J.; Scimeca, J.A. Conjugated
linoleic acid suppresses mammary carcinogenesis and proliferative
activity of the mammary gland in the rat. Cancer Res. 54:1212-1215;
1994.
24.) Ip, C.; Jiang, C.; Thompson, H.J.; Scimeca, J.A. Retention of
conjugated linoleic acid in the mammary gland is associated with
tumor inhibition during the post-initiation phase of carcinogenesis.
Carcinogenesis 18:755-759; 1997.
25.) Belury, M.A.; Vanden Heuvel, J.P. Protection against cancer and
heart disease by the dietary fat, conjugated linoleic acid: potential
mechanisms of action (Invited review) Nutr. Dis. Update J. 1:58-63;
1997.
26.) Zu, H.-X.; Schut, H.A.J. Inhibition of 2-amino-3-
methylimidazo[4,5-f] quinoline-DNA adduct formation in CDF-1 mice
by heat-altered derivatives of linoleic acid. Food Chem. Toxicol. 30:9-
16; 1992.
27.) Liew, C.; Schut, H.A.J.; Chin, S.F.; Pariza, M.W.; Dashwood, R.H.
Protection of conjugated linoleic acids against 2-amino-3-
methylimidazo[4/5-f] quinoline-induced colon carcinogenensis in the
F344 rat – a study of inhibitory mechanisms. Carcinogenesis 16:3037-
3043; 1995.
28.) Ha, Y.L.; Storkson, J.; Pariza, M.W. Inhibition of benzo(a)pyreneinduced
mouse forestomach neoplasia by conjugated dienoic
derivatives of linoleic acid. Cancer Res. 50:1097-1101; 1990.
29.) Lee, K.N.; Kritchevsky, D.; Pariza, M.W. Conjugated linoleic acid
and atherosclerosis in rabbits. Atherosclerosis 108:19-25; 1994.
6
43.) Park, Y.S.; Behre, R.A.; McGuire, M.A.; Shultz, T.D.; McGuire,
M.K. Dietary conjugated linoleic acid (CLA) and CLA in human milk.
FASEB J. 11:A239; 1997.
44.) Fogerty, A.C.; Ford, G.L.; Svoronos, D. Octadeca-9,11-dienoic
acid in food stuffs and in the lipids of human blood and breast milk.
Nutr. Rpt. Int’l. 38:937-944; 1988.
45.) Parodi, P.W. Conjugated linoleic acid: an anticarcinogenic fatty
acid present in milk fat. Aust. J. Dairy Technol. 49:93-97; 1994.
46.) Jahreis, G. Anticarcinogenic fatty acids in milk and beef.
Ernahrungs. Umschau. 44:168-172; 1997.
47.) Fritsche, J.; Steinhart, H. Amounts of conjugated linoleic acid
(CLA) in German foods and evaluation of daily intake. Z. Lebensm.
Unters. Forsch A. 206:77-82; 1998.
48.) Agrawal, S.; Heimbach, J.T.; Amann, M.M.; Mohammedshah, F.;
Douglas, J.S. Relative intakes of conjugated linoleic acid (CLA) from
meat and dairy products as a function of sex and age. J.Am.Col.Nutr.
17(5):526 (abstr. 118); 1998.
49.) Ritzenthaler, K.; McGuire, M.K.; Falen, R.; Shultz, T.D.; McGuire,
M.A. Documentation of rumenic acid (RA) intake by 3-day written
record, 3-day food duplicate and food frequency questionnaire.
Am.J.Clin.Nutr. (In press); 1999.
50.) Pariza, M.W. Conjugated linoleic acid, a newly recognized
nutrient. Chem. & Indust. 464-466; 1997.
For more information, contact:
Nutrition Research
National Cattlemen’s Beef Association
444 North Michigan Ave.
Chicago, IL 60611
(312) 467-5520
This fact sheet was developed by the National
Cattlemen’s Beef Association as part of a coordinated
effort with State Beef Council ‘s and the Beef Board.
©1999 National Cattlemen’s Beef Association
30.) Nicolosi, R.J.; Rogers, E.J.; Kritchevsky, D.; Scimeca, J.A.; Huth,
P.J. Dietary conjugated linoleic acid reduces plasma lipoproteins and
early aortic atherosclerosis in hypersholesterolemic hamsters. Artery
22:266-277; 1997.
31.) Park, Y.; Albright, K.J.; Liu, W.; Storkson, J.M.; Cook, M.E.; Pariza,
M.W. Effect of conjugated linoleic acid on body composition in mice.
Lipids 32:853-858; 1997.
32.) West, D.B.; Delany, J.P.; Camet, P.M.;Blohm, F.; Truett, A.A.;
Scimeca, J. Effects of conjugated linoleic acid on body fat and energy
metabolism in the mouse. Am. J. Physiol. 44:R667-R672; 1998.
33.) Cook, M.E.; Jerome, D.L.; Buege, D.R.; Russell, R.L.; Crenshaw,
T.C.; Storkson, J.; Albright, K.; Liu, W.; Park, Y.; Pariza, M.W.;
Scimeca, J.A.; Lofgren, P.; Hentges, E. Conjugated linoleic acid (CLA)
reduces backfat thickness, increases percent lean and improves feed
efficiency in pigs. Food Research Institute, Univ. Wisconsin, 1997
Annual Mtg. (poster abstr.); 1997.
34.) Chin, S.F.; Storkson, J.M.; Albright, K.J.; Cook, M.E.; Pariza, M.W.
Conjugated linoleic acid is a growth factor for rats as shown by
enhanced weight gain and improved feed efficiency. J. Nutr.
124:2344-2349; 1994.
35.) Seifert, M.F.; Watkins, B.A. Role of dietary lipid and antioxidants
in bone metabolism. Nutr. Res. 17:1209-1228; 1997.
36.) Li, Y.; Watkins, B.A. Conjugated linoleic acids alter bone fatty
acid composition and reduce ex vivo prostaglandin E-2 biosynthesis in
rats fed n-6 or n-3 fatty acids. Lipids 33:417-425; 1998.
37.) Houseknecht, K.L.; Vanden Heuvel, J.P.; Moya-Camarena, S.Y.;
Portocarrero, C.P.; Peck, L.W.; Nickel, K.P.; Belury, M.A. Dietary
Conjugated Linoleic Acid Normalizes Impaired Glucose Tolerance in
the Zucker Diabetic Fatty fa/fa Rat. Biochem. Biophys. Res. Commun.
244:678-682; 1998.
38.) Knekt, P.; Jarvinen, R.; Seppanen, R.; Pukkala, E.; Aromaa, A.
Intake of dairy products and the risk of breast cancer. Br. J. Cancer
73:687-691; 1996.
39.) Jain, M. Dairy food, dairy fats, and cancer – a review of epidemiological
evidence. Nutr. Res. 18:905-937; 1998.
40.) Lavillonniere, F.; Riboli, E.; Martin, J.C.; Lhuillery, C.; Chajes, V.;
Bougnoux, P. High conjugated linoleic acids (CLA) content in breast
adipose tissue protects against breast cancer. European Section AOCS
(abstr); 1998.
41.) Britton, M.; Fong, C.; Wickens, D.; Yudkin, J. Diet as a source of
phospholipid esterified 9,11 –octadecadienoic acid in humans. Clin.
Sci. 83:97-101; 1992.
42.) Huang, Y.-C.; Luedecke, L.O.; Shultz, T.D. Effect of cheddar
cheese consumption on plasma conjugated linoleic acid concentrations
in men. Nutr. Res. 14:373-386; 1994.
Special thanks is extended to Eric A. Decker, Ph.D., Univ. of Massachusetts, Amherst, MA for providing an independent review of
this report, in addition to the reviews provided by NCBA Nutrition staff.